Raymond James analyst Ryan Deschner initiated coverage of ARS Pharmaceuticals with an Outperform rating and $18 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals Updates Corporate Presentation Online
- ARS Pharmaceuticals: Corporate Update and EURneffy’s Positive Opinion
- ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals: EURneffy recommended for approval by CHMP